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Introduction
The hepatorenal syndrome [HRS]is a reversible functional acute
renal failure secondary to intense renal cortical vasoconstriction in a
patient with liver disease. It affects around 40% of patients with
cirrhosis and ascites1. The exact cause of the syndrome is not well 
understood. The state of liver dysfunction [Child-Pugh score] does
not predict the occurrence of the disease. 
Genetic factors play no important role
except as risk for liver disease and there is no sex
difference. Patients with HRS characteristically
have increased cardiac output, low arterial 
pressure, and reduced systemic vascular
resistance2
Diagnosis of HRS is one of exclusion.The 
definitive treatment is liver transplant. 
Nevertheless, a lot of work was done on medical 
therapy with promising results.
Pathogenesis
The pathogenesis of the disease is ill
defined. The structural hallmark of HPS is a 
reversible preferential renal vasoconstriction in 
the absence of reduced cardiac out put or blood 
volume. There are no histopathological changes in 
the kidneys and the tubules continue to reabsorb
sodium during the disease. The kidneys
transplanted from patients with HRS function 
normally in the recipients3. Preferential renal 
vasoconstriction with beading and tortuosity [Fig
A] which revert to normal when the patient dies
[Fig B] was proved using renal arteriography 4. 
It is clear that the imbalance between the 
systemic vasoconstrictor and the vasodilator
systems lead to this disease. Multiple theories
were put to explain the hemodynamic
disturbances seen in patients with HRS. 
The two main theories are the arterial 
vasodilatation theory and the hepatorenal reflex
theory. In the first theory systemic hypotension 
caused by the intense vasodilatation induced and
maintained by the high levels of nitric oxide-seen 
in patients with liver cirrhosis-is thought to 
activate the vasoconstrictive systems including
rennin-angiotenin-aldosteron system and the 
sympathetic nervous system resulting in 
peripheral vasoconstriction.
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However, the splanchnic vasodilatation 
does not respond to that because of local 
production of nitric oxide. Other vasoactive 
substances including adenosine, prostacycline,
endothelin 1, thromboxanes, prostaglandins, 
leukotrieneE4 and others may also contribute to
the pathogenesis of this disease. Whether
vasoconstrictor over activity or the vasodilator
system under activity is the predominant 
contributor to this has yet to be proven. The 
second theory states that renal hypoperfusion is a 
direct reflex to liver disease irrespective to the 
haemodynamic status of the patient and here 
hepatic underproduction of renal vasodilators is
thought to play a major ole. 
Fig A & B. The vascular changes in the kidney
before and after death in a patient with HRS 
Estimation of renal function
The decline in liver function and reduced 
muscle mass in patients with chronic liver disease 
occasionally lead to inappropriately low levels of
urea and creatinine and this usually mask the 
reduction in glomerular filteration rate. This
makes early detection of renal failure in these 
patients difficult.
Clinical presentation
Patients with the HRS classically present with the 
symptoms and signs of acute or chronic liver
disease. Virtually all patients have ascites and the 
majority have clinical evidence of portal
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hypertension. Features of oliguric renal failure 
usually supervene. 
Based upon the speed of onset of renal failure, 
two forms of hepatorenal syndrome have been 
described 5: 
• Type I hepatorenal syndrome which is 
characterized by the acute onset [within two 
weeks] of oliguric or anuric renal failure. 
• Type II hepatorenal syndrome which is more 
insidious (> 2 weeks) and less severe than type 1, 
with relatively better urine output. 
Gastrointestinal bleeding, rapid diuresis, 
paracentesis and infection were considered among 
the common triggering factors for the HRS6. Half 
of the patients have no identifiable precipitating 
factor. Spontaneous bacterial peritonitis 
precipitates HRS type 1 in approximately 20% of 
patients despite appropriate and timely diagnosis, 
treatment, and resolution of infection. 
HPS is uncommon in patients with primary biliary 
cirrhosis and this is attributed to the natriuretic 
and renal vasodilator effect of bile salts7 
Factors predictive for the development of 
HRS 
       Very low urinary sodium due to intense 
urinary sodium retention, dilutional hyponatremia, 
low blood pressure, decreased cardiac output, and 
increased activity of systemic vasoconstrictors are 
predictive factors for the onset of the syndrome8 
DIAGNOSIS 
There is no diagnostic test for the syndrome and 
so the diagnosis of HRS depends on the 
demonstration of renal failure in presence of liver 
disease and exclusion of interstitial renal disease 
including acute tubular necrosis, 
glomerulonephritis and pre-renal failure. 
International ascites club diagnostic 
criteria for diagnosis of HRS5 
Major criteria [All major criteria are required 
to diagnose HRS]: 
1. Chronic or acute hepatic disease and liver 
failure with portal hypertension 
2. Serum creatinine level >1.5 mg/dL (133 
micromoles/L) or 24-hr creatinine clearance <40 
mL/min (0.67 mL/s) 
3. Absence of shock, ongoing bacterial infection, 
recent use of nephrotoxic drugs, excessive fluid or 
blood loss 
4. No sustained improvement in renal function 
after volume expansion with 1.5 L isotonic saline 
solution 
5. Proteinuria <500 mg/day and no 
ultrasonographic evidence of renal tract or 
parenchymal disease 
Minor criteria [Additional criteria are not 
necessary for the diagnosis but provide supportive 
evidence]: 
1. Urine volume <500 mL/day 
2. Urine sodium <10 mEq/L 
3.Urine osmolality greater than plasma osmolality 
4. Urine red blood cell count <50 per high-power 
field 
Meticulous search for other causes of renal failure 
has to be carried out before this diagnosis is made 
as the management and the prognosis differ 
significantly. 
Treatment 
        HRS especially type 1 carries a poor 
prognosis. However, with increased 
understanding of the disease and its hemodynamic 
disturbances, promising new pharmacologic drugs 
and methods of treatments have emerged giving 
significant improvement in short-term outcomes. 
Improved liver function is the corner stone 
element in the treatment of the HRS. To date, 
recovery from acute liver insult if possible or liver 
transplantation is the only way for the cure of the 
disease9. Instant recovery of the renal failure 
occurs with improved liver function. The general 
management is that of renal failure and liver 
disease. Precipitating conditions-if identified- 
must be corrected. Keeping adequate circulation 
and good oxygenation of the blood is mandatory. 
Nephrotoxic drugs have to be stopped. 
Medical therapy: Despite through research to 
treat the HRS, drug therapy appears to be 
ineffective in persistently- long term- reversing 
the disease Interventions that have shown some 
promise are the agonists of vasopressin V1 
receptors, such as ornipressin and terlipressin, 
which have predominantly vasoconstrictor effects 
on the splanchnic circulation10. The rationale 
behind that is the theory of vasodilatation of the 
splanchnic circulation as the initial event in the 
development of HRS, and use of a vasoconstrictor 
may thus prevent homeostatic activation of 
endogenous vasoconstrictors. Other combination 
of drugs e.g.midodrine with octreotide and 
norepinephrine plus albumin infusion showed 
promising outcomes. The use of N-acetylcysteine, 
misoprstol, norepinephrine gave controversial 
results and need further studies. 
Transjugular intrahepatic portosystemic 
shunt (TIPS) 
      Despite the risk of hepatic encephalopathy 
TIPS- which has been used in the treatment of 
refractory ascites- is found to help some selected 
61
 Sudan JMS, Vol 1, No.1, Sept 2006 
patients who are not candidates for or are awaiting
liver transplantation11,12 
Dialysis 
Dialysis may buy time for patients awaiting liver 
transplantation and those wit h a c ut e  reversible 
liver insult. However, longterm survival following 
hemodialysis was reported13.  Nevertheless it is 
occasionally difficult to be performed in these 
patients because of the coaggulopathy and the 
disturbed hemodynamic. Hemofiltration was also
tried with some success14
.
Liver transplantation:
Despite the high risk of postoperative 
morbidity and early mortality and the need for 
pre- and postoperative hemodialysis for some 
time, liver transplantation remains to be the 
definitive treatment of the HRS15
.
Summary and recommendations:
HRS is a disease of ill defined pathogenesis. It 
is common in patients with liver cirrhosis and has 
significant morbidity and mortality.  Through look
and aggressive treatment for possible precipitant 
causes of renal failure in these patients is 
mandatory. Medical therapy gav e promising 
results. Nevertheless, liver transplant remains the 
gold standard treatment to save these patients.
Hemodialysis should be attempted while awaiting 
liver recovery or transplantation. A combination 
of midodrine and octreotide may be given to 
patients who are not candidates for 
transplantation. 
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